GlaxoSmithKline has teamed up with Xiamen Innovax Biotech to evaluate a vaccine against the novel coronavirus behind the COVID-19 pandemic. The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

GSK teamed up with Innovax last year to develop a human papillomavirus vaccine, tapping into the work of the Chinese biotech to drive its search for a successor to Cervarix.

The latest deal moves the partnership into COVID-19 and, in doing so, continues GSK’s effort to support the response to the pandemic SARS-CoV-2 virus through the provision of its AS03 adjuvant. Source: Fierce Biotech 3/4/20202